Skip to main content
REGN
NASDAQ Life Sciences

日本批准Dupixent作为首种针对性治疗水痘样天疱的靶向治疗手段，促进雷金纳的主要药物发展

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$736.53
Mkt Cap
$77.853B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

赛诺菲和雷金纳的Dupixent获得了日本的销售和制造授权，用于治疗成年人中度至重度水痘样天疱（BP），成为该慢性皮肤病的首种靶向药物。该批准基于关键研究结果，证明了使用Dupixent后疾病缓解率显著提高，这标志着该药在日本的第七个批准适应症。该积极的监管发展对于Dupixent来说是一个关键的收入增长点，如雷金纳最近的10-K所强调，强化了其增长轨迹，并扩大了其可进入的市场。进入一个新的、未充分满足的适应症是一个重大的积极因素，对于雷金纳来说，可能会为未来收入增长做出贡献。交易者将监测日本的商业推出和销售情况，以及其他主要市场可能获得类似批准的潜力。SEC和Form 4、8-K、CIK相关监管要求将继续影响雷金纳的财务报表，包括EBITDA和GAAP的计算和披露，公司的CIK编号也将在SEC的网站上公布，交易者可以通过Form 4和8-K了解公司高管的持股和交易情况，并通过公司的财务报表了解其EBITDA和GAAP的财务表现。

在该公告发布时，REGN的交易价格为$736.53，交易所为NASDAQ，所属行业为Life Sciences，市值约为$778.5亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article